Origent Data Sciences

Origent Data Sciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Origent Data Sciences is a private, revenue-generating AI/ML platform company founded in 2015. It leverages predictive analytics and natural language processing to address two core challenges in healthcare: the high cost/risk of clinical trials and the delayed diagnosis of complex diseases like ALS. Its technology suite includes predictive models for trial optimization, AI-driven clinical decision support tools for early detection, and the MyJourney app, an AI companion that captures patient-reported data. Origent's solutions target biopharma sponsors, CROs, clinicians, and patients, creating a new category of narrative-derived health intelligence.

Amyotrophic Lateral Sclerosis (ALS)Alzheimer's DiseaseNeurodegenerative Diseases

Technology Platform

AI/ML platform combining predictive analytics for clinical trial optimization (patient-level forecasting, virtual controls) with an AI health companion (MyJourney app) that uses NLP to transform unstructured patient narratives into structured, actionable health data and clinical decision support tools.

Opportunities

The massive and inefficient clinical trials market and the critical diagnostic delays in neurodegenerative diseases present a dual, multi-billion dollar addressable market.
The industry shift towards decentralized trials, digital endpoints, and patient-centricity accelerates demand for Origent's predictive and narrative data solutions.

Risk Factors

Key risks include commercialization challenges in a risk-averse industry, dependence on high-quality data for AI model training, intense competition in the AI-health space, and significant regulatory and data privacy hurdles associated with handling sensitive patient health information.

Competitive Landscape

Origent competes with generalist clinical trial AI companies (e.g., Unlearn.AI, Saama) and broader digital health platforms, but differentiates through its deep, proven specialization in ALS and neurodegenerative diseases. It also faces competition from other patient-facing symptom tracker and PRO apps, though its direct integration with clinical research and diagnostic support is a key differentiator.